treatment | Page 60 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

treatment

  1. Home

Glens Falls (NY) Virtual/In-Person Blood Cancer Support Group

C.R. Wood Cancer Center holds a blood cancer support group on the second Wednesday of each month at 6:00pm. At the meetings, blood cancer patients and their families will connect with each other and share experiences. This group has both in-person and virtual attendance options. To register or for questions, please contact - Karen Cook, LMSW, at (518) 926-6619.

C.R. Wood Cancer Center
Pruyn Pavilion at Glens Falls Hospital
100 Park Street
Glens Falls, NY 12801

Caring for Yourself

We help you cope with your battle against bone marrow failure disease. The information we provide teaches patients and families how to be proactive members of your health care team. Patients just like you have also learned how to develop their inner strength by connecting with our community and taking advantage of our resources.

Thalidomide

Currently it is approved by the U.S. Food and Drug Administration (FDA) for use in treating a skin disease associated with leprosy. Thalidomide is being studied, either as a single agent or in combination with other medicines, for treating of

Mycophenolate Mofetil

Mycophenolate mofetil is approved by the U.S. Food and Drug Administration (FDA) to prevent organ rejection in people who have received a kidney, heart, or liver transplant. This medicine comes as a capsule, tablet, or liquid that is taken by mouth. Researchers are currently studying MMF in combination with other medicines for treating

Lenalidomide

Lenalidomide is a capsule that is taken by mouth. It is approved for treating low-risk, transfusion-dependent myelodysplastic syndrome (MDS) patients with an abnormality of chromosome 5q. It is currently in clinical trials to test its efficacy with a broader range of MDS patients. For some MDS patients, lenalidomide can improve

Fludarabine

The U.S. Food and Drug Administration (FDA) approved fludarabine for treating chronic lymphocytic leukemia (CCL). Researchers are studying fludarabine in combination with other medicines for treating

Eculizumab

Eculizumab (Soliris ®) is given as an IV into a vein at the doctor’s office or at a special center. The procedure usually takes about 35 minutes. You will probably get an IV once a week for the first 4 weeks. Starting in the 5th week, you will get a slightly higher dose of Soliris every 2 weeks.

How well does it work?

Eculiziumab has many benefits. It has been found to: